Breaking News Instant updates and real-time market news.

BHC

Bausch Health

$23.56

0.29 (1.25%)

, SURF

Surface Oncology

$8.10

-0.15 (-1.82%)

07:55
11/27/18
11/27
07:55
11/27/18
07:55

Piper Jaffray to hold a conference

30th Annual Healthcare Conference will be held in New York on November 27-29 with webcasted company presentations to begin on November 27 at 8 am; not all company presentations may be webcasted. Webcast Link

BHC

Bausch Health

$23.56

0.29 (1.25%)

SURF

Surface Oncology

$8.10

-0.15 (-1.82%)

ARRY

Acquired by PFE

$15.92

0.27 (1.73%)

IMV

IMV Inc.

$5.52

(0.00%)

EBS

Emergent BioSolutions

$70.52

-0.87 (-1.22%)

ZYNE

Zynerba

$5.09

-0.09 (-1.74%)

CYTK

Cytokinetics

$7.68

0.44 (6.08%)

TDOC

Teladoc

$58.43

2.64 (4.73%)

CORV

Correvio

$3.42

0.01 (0.29%)

EXEL

Exelixis

$18.78

0.37 (2.01%)

NBRV

Nabriva Therapeutics

$1.94

-0.09 (-4.43%)

RARE

Ultragenyx

$55.58

2.34 (4.40%)

GERN

Geron

$1.53

0.03 (2.00%)

COX

No Longer Trades

$0.00

(0.00%)

CUE

Cue Biopharma

$5.17

-0.12 (-2.27%)

DCPH

Deciphera

$23.98

0.87 (3.76%)

COLL

Collegium Pharmaceutical

$18.98

0.65 (3.55%)

ATRS

Antares Pharma

$3.39

0.03 (0.89%)

RCUS

Arcus Biosciences

$11.24

-0.37 (-3.19%)

MNLO

Menlo Therapeutics

$6.47

0.08 (1.25%)

  • 27

    Nov

  • 27

    Nov

  • 29

    Nov

  • 10

    Dec

  • 12

    Dec

  • 14

    Jan

  • 15

    Feb

BHC Bausch Health
$23.56

0.29 (1.25%)

11/06/18
WELS
11/06/18
NO CHANGE
WELS
Underperform
Bausch Health continues to underspend on R&D to fuel upside, says Wells Fargo
Wells Fargo analyst David Maris said Bausch Health has been underspending on R&D to help fuel better than expected results and Q3 "was not different" in that respect. Of note, Bausch also announced it is starting an ongoing efficiency initiative, which would proactively reduce channel inventory in Q4. Maris continues to see Bausch Health shares carrying too much risk to recommend and keeps an Underperform rating on the stock.
11/19/18
WELS
11/19/18
NO CHANGE
WELS
Underperform
Wells says Aemcolo approval step toward eventual slowdown for Bausch's Xifaxan
Wells Fargo analyst David Maris noted that Cosmo Pharmaceuticals received approval of Aemcolo for traveler's diarrhea after the close on Friday, November 16. Bausch Health has previously indicated that traveler's diarrhea accounted for less than 10% of Xifaxan sales and they do not see approval of a competing product in TD alone as significant, though Maris said he disagrees with that assessment. He also believes this approval means Aemcolo is more likely to be approved in IBS-D. Maris, who views this news as the first step toward an eventual slowdown, and potentially a decline, in revenues for Xifaxan, keeps an Underperform rating on Bausch Health shares.
11/05/18
11/05/18
UPGRADE
Target $32

Overweight
Bausch Health upgraded to Overweight on improving growth at Morgan Stanley
As previously reported, Morgan Stanley analyst David Risinger upgraded Bausch Health to Overweight from Equal Weight, as he expects improved growth in 2020, a mix shift toward new products and gradual debt paydown to drive the stock's multiple higher. He continues to project Q3 EBITDA of $850M, 5% above consensus, and sees the upcoming quarterly report as a potential catalyst to drive the stock up, Risinger added. He set a $32 price target on Bausch Health shares.
11/05/18
MSCO
11/05/18
UPGRADE
MSCO
Overweight
Bausch Health upgraded to Overweight from Equal Weight at Morgan Stanley
SURF Surface Oncology
$8.10

-0.15 (-1.82%)

05/14/18
EVER
05/14/18
INITIATION
Target $26
EVER
Outperform
Surface Oncology initiated with an Outperform at Evercore ISI
Evercore ISI analyst Josh Schimmer initiated Surface Oncology with an Outperform and $26 price target telling investors the company is developing a portfolio of programs that target the immuno-suppresive tumor microenvironment which helps to 'hide' cancer cells from attack by the immune system. The analyst said lead CD47 antibody cancer I/O program is very compelling, with the most exciting aspect of Surface being a terrific management team with multiple shots on goal, providing a meaningful backstop on valuation should the lead program stumble.
09/18/18
BARD
09/18/18
INITIATION
Target $23
BARD
Outperform
Surface Oncology initiated with an Outperform at Baird
Baird analyst Michael Ulz initiated Surface Oncology with an Outperform and $23 price target.
05/14/18
05/14/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. General Electric (GE) initiated with a Buy at Gabelli. 2. Western Digital (WDC) initiated with an Overweight at JPMorgan. 3. GrafTech (EAF) initiated with an Overweight at JPMorgan and an Outperform at RBC Capital. 4. Surface Oncology (SURF) initiated with an Outperform at Evercore ISI and Cowen as well as a Neutral at Goldman Sachs. 5. BeiGene (BGNE) initiated with an Outperform at Credit Suisse. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/14/18
GSCO
05/14/18
INITIATION
Target $17
GSCO
Neutral
Surface Oncology initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst Salveen Richter initiated Surface Oncology with a Neutral and $17 price target. Richter said the key value driver is SRF 231, which prevents the immune system from recognizing and targeting cancer cells, and in Phase 1 in solid tumors and blood cancers. THe analyst said SRF231 could be a best-in-class asset, but looks for preclinical data translation in humans before becoming more constructive on shares.
ARRY Acquired by PFE
$15.92

0.27 (1.73%)

09/17/18
GUGG
09/17/18
INITIATION
GUGG
Guggenheim calls Array, Deciphera, ImmunoGen top biotech picks
Guggenheim initiated coverage of the biotechnology sector, initiating and assuming coverage of 17 biotechnology stocks, and saying it is bullish on the sector longer term and expects continued growth. The firm's coverage focuses on the oncology therapeutic category, with Guggenheim calling Array Biopharma (ARRY), Deciphera Pharmaceuticals (DCPH), and ImmunoGen (IMGN), which all have key catalysts coming in the first half or 2019, its top picks.
08/14/18
PIPR
08/14/18
NO CHANGE
Target $25
PIPR
Overweight
Piper Jaffray 'surprised' Array BioPharma shares are trading lower post-results
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $25 price target for Array BioPharma following the company's Q4 results, telling investors in a research note that he is "surprised" to see shares trading lower today on a "perceived" revenue miss. Tenthoff, who notes that revenues in Q4 were only reimbursement and milestones from partners, says he is a buyer for the Braftovi and Mektovi launch in BRAF-mutant melanoma, which occurred the week of July 2, and projects initial sales of $17.2M in calendar 2018 and $71.5M in calendar 2019.
08/16/18
JEFF
08/16/18
NO CHANGE
Target $18
JEFF
Buy
After doc survery, Jefferies sees Array melanoma combo estimates as 'achievable'
After conducting a poll of 31 U.S. oncologists on Array Biopharma's recently approved Braftovi/ Mektovi combo treatment for melanoma, Jefferies analyst Eun Yang said the survey leads her to believe her U.S. sales estimate of about $300M in FY2022 seems "quite achievable." Given the poll, she views downside risks for Array shares as limited and maintains a Buy rating and $18 price target on the shares.
09/17/18
GUGG
09/17/18
INITIATION
Target $32
GUGG
Buy
Array BioPharma initiated with a Buy at Guggenheim
Target $32.
IMV IMV Inc.
$5.52

(0.00%)

EBS Emergent BioSolutions
$70.52

-0.87 (-1.22%)

11/02/18
CANT
11/02/18
NO CHANGE
Target $75
CANT
Overweight
Emergent BioSolutions price target raised to $75 from $68 at Cantor Fitzgerald
Cantor Fitzgerald analyst Brandon Folkes raised his price target for Emergent BioSolutions to $75 and reiterates an Overweight rating on the shares following the company's Q3 results. The analyst views the acquisitions of PaxVax and Adapt as providing visibility into the company's path to $1B-plus in revenue, which he now expects it to achieve next year. He calls Emergent the "best defensive stock to own in our coverage universe."
11/02/18
GSCO
11/02/18
UPGRADE
Target $75
GSCO
Buy
Emergent BioSolutions upgraded to Buy with $75 target at Goldman Sachs
Goldman Sachs analyst Dana Flanders upgraded Emergent BioSolutions to Buy and raised his price target for the shares to $75 from $60. The analyst sees an "underappreciated opportunity" for Emergent to expand into other verticals, highlighted by Narcan nasal spray. Further, the company can continue with high return on invested capital acquisitions given that is few competitors of scale, Flanders tells investors in a research note. While the stock is not "cheap," a premium valuation is warranted given Emergent's "sticky and growing base business with high barriers to entry," contends Flanders.
11/02/18
GSCO
11/02/18
UPGRADE
Target $75
GSCO
Buy
Emergent BioSolutions upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Dana Flanders upgraded Emergent BioSolutions to Buy and raised his price target for the shares to $75 from $60.
11/02/18
11/02/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Emergent BioSolutions (EBS) upgraded to Buy from Neutral at Goldman Sachs with analyst Dana Flanders saying he sees an "underappreciated opportunity" for Emergent to expand into other verticals, highlighted by Narcan nasal spray. 2. Michael Kors (KORS) upgraded to Buy from Neutral at UBS and to Overweight from Neutral at Piper Jaffray. 3. Parker-Hannifin (PH) upgraded to Outperform from Market Perform at Wells Fargo with analyst Andrew Casey sayoing the recent selloff has created an opportunity "to get back on board the PH stock train." 4. Ingredion (INGR) upgraded to Neutral from Sell at Citi with analyst David Driscoll saying the worst is now likely behind the company's North American operations, which should resume growth in 2019 "when many of the transitory 2018 issues will be in the rear view mirror." 5. VeriSign (VRSN) upgraded to Neutral from Underweight at JPMorgan and to Outperform from Neutral at Baird. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
ZYNE Zynerba
$5.09

-0.09 (-1.74%)

08/06/18
HCWC
08/06/18
NO CHANGE
Target $23
HCWC
Buy
Zynerba 46% pullback since financing unwarranted, says H.C. Wainwright
Shares of Zynerba Pharmaceuticals are down 46% since the company announced a $30M financing late July, and down 30% from where it priced at $8 per share, H.C. Wainwright analyst Oren Livnat tell investors in a research note. The analyst views the stock weakness as unwarranted. The ZYN002 programs are on track for key 2019 readouts, Livnat points out. He believes Zynerba's current valuation "belies even highly risk-discounted opportunities." The analyst is "perplexed by the extreme ZYNE pullback." Livnat says he's not aware of any erosion of Zynerba's fundamentals or prospects. The analyst reiterates aBuy rating on Zynerba with a $23 price target.
09/21/18
CANT
09/21/18
INITIATION
Target $21
CANT
Overweight
Zynerba initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan last night initiated coverage of Zynerba with an Overweight rating and $21 price target. The analyst, who started coverage on seven Neuro-Innovator and Platform-Enabled Therapeutic companies, believes that "biotech has entered a golden age of innovation and productivity across many therapeutic areas."
04/16/18
HCWC
04/16/18
NO CHANGE
Target $23
HCWC
Buy
Zynerba shares remain undervalued, says H.C. Wainwright
Zynerba Pharmaceuticals and its pipeline "could gain incremental visibility and appreciation with immediate and near-term catalysts," H.C. Wainwright analyst Oren Livnat tells investors in a research note. The analyst continues to believe the company is undervalued. His $23 price target is based exclusively on 35% probability of success of ZYN002 - synthetic cannabidiol transdermal gel - in Fragile X syndrome. The analyst does not yet include any credit for potential ZYN002 epilepsy indications. Investors may soon begin to give more credit to this indication with two catalysts this month, Livnat writes. He reiterates a Buy rating on Zynerba.
07/05/18
HCWC
07/05/18
NO CHANGE
Target $23
HCWC
Buy
Zynerba failed program not material negative, says H.C. Wainwright
Zynerba Pharmaceuticals this morning announced it is discontinuing development of its transdermal THC pro-drug patch ZYN001 after a Phase 1 study in healthy subjects failed to deliver the targeted potential therapeutic blood levels. This development is not a material negative, H.C. Wainwright analyst Oren Livnat tells investors in a research note. The analyst says he never included ZYN001 for Tourette's or any other indication in his estimates or valuation. He notes that his valuation is entirely based on orphan designated ZYN002 transdermal cannabidiol gel for Fragile X syndrome, entering Phase 3 shortly, "with upside optionality from ongoing work in refractory and rare epilepsies." Livnat views the early-stage ZYN001 termination "as a sign of responsible drug development" and keeps a Buy rating on Zynerba with a $23 price target. The stock in afternoon trading is down 54c to $9.07.
CYTK Cytokinetics
$7.68

0.44 (6.08%)

09/21/18
CANT
09/21/18
INITIATION
Target $14
CANT
Overweight
Cytokinetics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan last night initiated coverage of Cytokinetics with an Overweight rating and $14 price target. The analyst, who started coverage on seven Neuro-Innovator and Platform-Enabled Therapeutic companies, believes that "biotech has entered a golden age of innovation and productivity across many therapeutic areas."
10/05/18
HCWC
10/05/18
NO CHANGE
Target $21
HCWC
Buy
Cytokinetics price target lowered to $21 from $24 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis lowered his price target on Cytokinetics shares to $21 from $24 after partner Astellas reported that both primary and secondary endpoints were not met in a trial of reldesemtiv in COPD patients and another trial testing reldesemtiv in elderly frailty was discontinued. However, omecamtiv drives the "lion's share" of his valuation of Cytokinetics shares, said Pantginis. The analyst, who noted that the omecamtiv mecarbil pivotal programs are progressing as planned, keeps a Buy rating on the stock.
10/05/18
MSCO
10/05/18
NO CHANGE
Target $10
MSCO
Equal Weight
Cytokinetics' reldesemtiv Phase 2 miss not a surprise, says Morgan Stanley
After Cytokinetics and partner Astellas announced that their Phase 2 study of reldesemtiv in COPD did not meet the primary endpoint and did not demonstrate a significant difference in any secondary endpoints, Morgan Stanley analyst Jeffrey Hung said he was not surprised by the "disappointing" results since Cytokinetics management has been suggesting for at least a month that the results from both COPD and frailty would be used to guide development of another compound rather than reldesemtiv. The upcoming R&D Day will focus on the cardiac muscle franchise, added Hung, who keeps an Equal Weight rating and $10 price target on Cytokinetics shares.
10/05/18
PIPR
10/05/18
NO CHANGE
Target $13
PIPR
Overweight
Piper focus for Cytokinetics remains ALS, SMA after reldesemtiv fails in COPD
After Cytokinetics and partner Astellas announced that reldesemtiv failed in a Phase 2 study in COPD and Phase 1b in frailty, Piper Jaffray analyst Edward Tenthoff noted that he had not valued reldesemtiv in either of these indications. The analyst, who said he remains focused on the indications of Spinal Muscular Atrophy and Amyotrophic Lateral Sclerosis, keeps an Overweight rating and $13 price target on Cytokinetics shares.
TDOC Teladoc
$58.43

2.64 (4.73%)

10/25/18
ADAM
10/25/18
NO CHANGE
Target $94
ADAM
Buy
Canaccord sees potential bias to upside for Teladoc guidance
Canaccord analyst Richard Close remains bullish on Teladoc ahead of next week's Q3 results. The analyst noted last month's updated guidance at its analyst meeting, so he is not expecting any surprises, but he does see a potential bias to the upside for guidance. Close reiterated his Buy rating and $94 price target on Teladoc shares.
11/02/18
JEFF
11/02/18
NO CHANGE
Target $95
JEFF
Buy
Teladoc remains a favorite idea after Q3 beat at Jefferies
Teladoc reported Q3 results that were better than expected and increased its revenue guidance ahead of Street estimates, Jefferies analyst Sean Dodge tells investors in a post-earnings research note. Teladoc remains the analyst's favorite idea, "especially on the recent pullback." He keeps a Buy rating on the shares with a $95 price target.
11/13/18
ADAM
11/13/18
NO CHANGE
Target $94
ADAM
Buy
Teladoc reaffirmed as a Top Pick at Canaccord
Canaccord analyst Richard Close reaffirmed Teladoc as a Top Pick following investor meetings with management. The analyst said management defended the business practices at BetterHelp, which has come under criticism, while reiterating solid growth in its other business lines. Close recommends taking advantage of the recent pullback as he has greater confidence in the company's growth outlook after meeting with management. Close reiterated his Buy rating and $94 price target on Teladoc shares.
11/16/18
PIPR
11/16/18
NO CHANGE
PIPR
Overweight
Telemedicine industry remains in growth stage, says Piper Jaffray
After surveying 172 human resource executives to ascertain the market demand and opportunity for telemedicine services, Piper Jaffray analyst Sean Wieland reiterates an Overweight rating on Teladoc (TDOC). While new entrants are gaining share in the employer market, the "pie is growing, and much greenfield remains," Wieland tells investors in a research note. He believes pricing power is strong and demand for telemedicine services continues to rise. Teladoc is well positioned for growth as employers add behavioral, second opinion, and international capabilities, says the analyst. He believes the telemedicine industry continues to be in a growth stage.
CORV Correvio
$3.42

0.01 (0.29%)

10/10/18
ADAM
10/10/18
NO CHANGE
Target $8
ADAM
Buy
Correvio weakness a buying opportunity, says Canaccord
Canaccord analyst Dewey Steadman said the recent weakness in Correvio is a buying opportunity as he sees no negative news on the story. The analyst said the company has an FDA meeting this month to discuss the path forward for Brinavess and he is very positive on the potential for news and sees it as a positive catalyst. Steadman reiterated his Buy rating and $8 price target on Correvio shares.
EXEL Exelixis
$18.78

0.37 (2.01%)

09/21/18
PIPR
09/21/18
NO CHANGE
Target $29
PIPR
Overweight
Piper Jaffray reiterates Overweight rating on Exelixis after CHMP decision
After Ipsen (IPSEY) announced a positive CHMP decision for Cabometyx as a monotherapy for the treatment of hepatocellular carcinoma, Piper Jaffray analyst Edward Tenthoff noted that Exelixis (EXEL) is eligible for tiered royalties of 22-26% after $100M in sales of the drug in Europe. He expects final EMA approval in coming months and also expects the FDA to approve Cabometyx in liver cancer by the January 14 PDUFA date, Tenthoff tells investors. He reiterated an Overweight rating and $29 price target on Exelixis shares.
11/02/18
NEED
11/02/18
NO CHANGE
Target $30
NEED
Buy
Exelixis well positioned for future I/O combos, says Needham
Needham analyst Chad Messer said cabozantinib is "becoming the drug of choice in second line treatment in RCC" and he believes immuno-oncology combos will support future growth. Exelixis is running several clinical programs investigating cabozantinib in combination with I/O drugs, noted Messer, who keeps a Buy rating and $30 price target on Exelixis following the company's Q3 report.
11/04/18
PIPR
11/04/18
NO CHANGE
Target $26
PIPR
Overweight
Exelixis price target lowered to $26 from $29 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff lowered his price target for Exelixis to $26 from $29, while reiterating an Overweight rating on the shares. The analyst notes the company delivered another beat with U.S. CABOMETYX sales of $158M in Q3. Although I-O is beginning to dominate front-line RCC, Tenthoff believes CABO is competitively positioned in certain patients and with ongoing I-O combo studies of its own. Next, he expects CABOMETYX label expansion in hepatocellular carcinoma with approval by the January 14th PDUFA date. The analyst now forecasts CABOMETYX sales of $595M in 2018, $826M in 2019, peaking at $1.38B in 2024.
10/08/18
PIPR
10/08/18
NO CHANGE
PIPR
Piper Jaffray optimistic on Exelixis' Cabometyx
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $29 price target on Exelixis. The analyst noted that Exelixis initiated a Phase III trial of Cabometyx in radioiodine-refractory differentiated thyroid cancer, or DTC. He is looking for continued Cabometyx adoption in first and second-line renal cell carcinoma with sales of $572M this year, and sees Cabometyx approval in 2nd-line liver cancer by the January 14 PDUFA date, which will help drive sales to $873M in 2019.
NBRV Nabriva Therapeutics
$1.94

-0.09 (-4.43%)

05/31/18
NORL
05/31/18
INITIATION
Target $17.5
NORL
Outperform
Nabriva Therapeutics initiated with an Outperform at Northland
Northland initiated Nabriva Therapeutics with an Outperform and $17.50 price target.
08/27/18
BOFA
08/27/18
NO CHANGE
Target $5
BOFA
Buy
Nabriva Therapeutics price target lowered to $5 from $9 at BofA/Merrill
BofA/Merrill analyst Jason Gerberry lowered his price target on Nabriva Therapeutics to $5, citing his lower expected probability of success of 60% vs. 75% prior in its recently acquired CONTEPO for complicated urinary tract infection. The analyst says the program's main risk is an "imbalance of liver enzyme elevation while a slightly higher dose reduces read -through from about a 45-year post-market EU safety". Gerberry now believes that CONTEPO is a "niche opportunity", and lowers his peak sales view to $50M from $80M prior. The analyst also keeps his Buy rating on Nabriva on valuation as well as the opportunity for its two FDA action dates for lefamulin and CONTEPO in the second half of 2019.
11/14/18
RHCO
11/14/18
NO CHANGE
Target $11
RHCO
Buy
Nabriva Therapeutics price target lowered to $11 from $16 at SunTrust
SunTrust analyst Edward Nash lowered his price target on Nabriva Therapeutics to $11 after its Q3 earnings and the management's recent NDR presentation. The analyst says the company has disclosed that it has filed an NDA for Contepo in cUTI and plans to submit an NDA for lefamulin in community-acquired bacterial pneumonia with intention to price both drugs competitively to encourage their early use. Nash states that his lowered price target reflects the company's competitive pricing strategy but also keeps his Buy rating on Nabriva Therapeutics to reflect the potential of its treatments longer term.
09/07/18
MSCO
09/07/18
INITIATION
Target $8
MSCO
Overweight
Nabriva Therapeutics resumed with an Overweight at Morgan Stanley
Morgan Stanley analyst David Lebowitz resumed coverage of Nabriva Therapeutics with an Overweight rating and a $8 price target, stating that its "first-in-class" antibiotics lefamulin and Contepo both have approvable Phase 3 data. He believes at current levels Nabriva shares are pricing in a "worst case scenario" for both antibiotics, but he sees it as likely that Nabriva exceeds the low expectations. Lebowitz forecasts risk-adjusted 2025 sales for lefamulin and Contepo of $228M and $33M, respectively.
RARE Ultragenyx
$55.58

2.34 (4.40%)

11/08/18
SBSH
11/08/18
UPGRADE
Target $54
SBSH
Neutral
Ultragenyx upgraded to Neutral from Sell at Citi
Citi analyst Yigal Nochomovitz upgraded Ultragenyx to Neutral and raised his price target for the shares to $54 from $46.
11/07/18
ADAM
11/07/18
NO CHANGE
Target $75
ADAM
Buy
Ultragenyx price target lowered to $75 from $90 at Canaccord
Canaccord analyst Arlinda Lee lowered her price target on Ultragenyx to $75 from $90, citing the announced discontinuation of triheptanoin development, which she removed from her model. Lee reiterated her Buy rating on Ultragenyx shares, noting its first commercial launches of Crysvita and Mepsevil are under way.
11/08/18
SBSH
11/08/18
UPGRADE
Target $54
SBSH
Neutral
Citi upgrades Ultragenyx to Neutral with valuation concerns playing out
Citi analyst Yigal Nochomovitz upgraded Ultragenyx to Neutral from Sell and raised his price target for the shares to $54 from $46. The analyst says his long-standing concerns on Ultragenyx's valuation "have substantially played out with recent pipeline disclosures having rapidly reset the valuation." He also acknowledges that the pace of Crysvita adoption has exceeded his expectations. However, he believe Crysvita's value is fully reflected in the stock at current levels. The upside/downside of the stock is now dependent on progress with Ultragenyx's gene therapy pipeline and the regulatory/commercial path for UX-007, Nochomovitz tells investors in a research note.
11/08/18
11/08/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Archer Daniels (ADM) upgraded to Buy from Hold at Argus with analyst Deborah Ciervo citing the company's recent strong performance and improvement in its Oilseeds, Origination, and Nutrition divisions. 2. Ultragenyx (RARE) upgraded to Neutral from Sell at Citi with analyst Yigal Nochomovitz saying his long-standing concerns on Ultragenyx's valuation "have substantially played out with recent pipeline disclosures having rapidly reset the valuation." 3. Medifast (MED) upgraded to Buy from Neutral at Sidoti. 4. Knight-Swift (KNX) upgraded to Buy from Neutral at Goldman Sachs with analyst Matthew Reustle saying he is bullish on Knight citing incremental evidence that the merger with Swift Transportation will deliver margin improvement through the end of the decade, reduced investor expectations following recent estimate revisions, and a view that Knight is more defensive through a down-cycle with a de-risked valuation. 5. Axon (AAXN) Enterprise upgraded to Overweight from Neutral at JPMorgan with analyst Mark Strouse saying the stock pulled back 16% yesterday following the company's Q3 results and guidance that implies a dip in revenue growth during Q4. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
GERN Geron
$1.53

0.03 (2.00%)

10/02/18
RILY
10/02/18
DOWNGRADE
Target $1.5
RILY
Neutral
Geron downgraded to Neutral from Buy at B. Riley FBR
B. Riley FBR analyst George Zavoico downgraded Geron to Neutral and lowered his price target for the shares to $1.50 from $5.75. The analyst revised his outlook for imetelstat after Jannsen ended its collaboration with the company.
03/19/18
PIPR
03/19/18
NO CHANGE
Target $7
PIPR
Overweight
Geron price target raised to $7 from $5 at Piper Jaffray
Piper Jaffray analyst Charles Duncan raised his price target for Geron to $7 after the company this morning reported year-end 2017 cash of $109M and provided an update on its IMerge and IMbark studies. The analyst projects the current cash will fund Geron's operations into 2020. He's encouraged by the update on the IMbark study in myelofibrosis and reiterates an Overweight rating on the shares.
07/05/18
RILY
07/05/18
INITIATION
Target $5.75
RILY
Buy
Geron initiated with a Buy at B. Riley FBR
B. Riley FBR analyst George Zavoico started Geron with a Buy rating and $5.75 price target.
COX No Longer Trades
$0.00

(0.00%)

CUE Cue Biopharma
$5.17

-0.12 (-2.27%)

09/28/18
RILY
09/28/18
INITIATION
Target $14.5
RILY
Buy
Cue Biopharma initiated with a Buy at B. Riley FBR
B. Riley FBR analyst George Zavoico started Cue Biopharma with a Buy rating and $14.50 price target.
DCPH Deciphera
$23.98

0.87 (3.76%)

11/16/18
LEER
11/16/18
NO CHANGE
Target $20
LEER
Outperform
Deciphera price target lowered to $20 from $28 at Leerink
Leerink analyst Andrew Berens lowered his price target for Deciphera Pharmaceuticals (DCPH) to $20 from $28 and reiterates an Underperform rating on the name. The updated data for avapritinib from Blueprint Medicines (BPMC) in gastro-intestinal stromal tumors reaffirmed a leading position in PDGFRalpha and 4L GIST, and demonstrated early activity in 2L patients, Berens tells investors in a research note. He believes this challenges key tenets of Dicephera's DCC-2618 value proposition. The analyst also thinks the weakness in Blueprint shares yesterday was due in part to a misunderstanding of the early second-line data that were presented, in addition to the safety concerns. Berens keeps an Outperform rating on Blueprint.
10/19/18
PIPR
10/19/18
NO CHANGE
Target $50
PIPR
Overweight
Piper remains 'aggressive' buyer of Deciphera after 'derisking' data
Piper Jaffray analyst Christopher Raymond says he remains an "aggressive" buyer of Deciphera Pharmaceuticals and that the shares should recover this morning following the company's DCC-2618 gastrointestinal stromal tumors data presentation at the European Society of Medical Oncology meeting. With the backdrop of some investor concern that the data would bring an equivocal comp for DCC-2618 to Sutent, initial durability compares well as the ~9.7 month progression free survival in second-line GIST appears "decisively ahead" of Sutent's 6.1 months, "derisking" the Phase 3 head-to-head trial, Raymond tells investors in a research note. The analyst keeps an Overweight rating on Deciphera with a $50 price target.
09/24/18
LEER
09/24/18
INITIATION
Target $28
LEER
Underperform
Deciphera initiated with an Underperform at Leerink
Leerink analyst Andrew Berens started Deciphera Pharmaceuticals with an Underperform rating and $28 price target.
11/15/18
PIPR
11/15/18
NO CHANGE
Target $50
PIPR
Overweight
Deciphera remains well positioned after Blueprint data, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on Deciphera Pharmaceuticals (DCPH) following the presentation of gastrointestinal tumors data from Blueprint Medicines' avapritinib at the Connective Tissue Oncology Society meeting. While avapritinib second-line data looks comparable to Deciphera's DCC-2618, this included patients dosed at higher levels than what is going forward commercially and into registration trials, Raymond tells investors in a research note. In later lines avapritinib's overall response rate was higher than DCC-2618 but other measures are almost indistinguishable, says the analyst. Raymond views the efficacy data as "relatively comparable" between the two agents but says Deciphera's DCC-2618 has a "far better safety profile." As such, he continues to see the company as well positioned in gastrointestinal tumors. Deciphera is up 11% to $22.94 in morning trading while Blueprint is down 6% to $52.70.
COLL Collegium Pharmaceutical
$18.98

0.65 (3.55%)

10/24/18
CANT
10/24/18
NO CHANGE
Target $35
CANT
Overweight
Collegium selloff brings 'compelling entry point,' says Cantor Fitzgerald
Cantor Fitzgerald analyst Brandon Folkes believes the recent weakness in shares of Collegium Pharmaceutical presents a "compelling entry point for investors." The analyst remains positive on Collegium's long-term ability to capture the majority of the branded OxyContin market. Despite the tempered Xtampza script growth, the company should meet consensus Xtampza numbers when reporting Q3 earnings, Folkes tells investors in a research note. He keeps an Overweight rating on the shares with a $35 price target.
06/21/18
CANT
06/21/18
NO CHANGE
Target $40
CANT
Overweight
Collegium to benefit from Purdue's issues, says Cantor Fitzgerald
Purdue Pharma yesterday confirmed it has laid off an additional 350 employees, including the company's remaining sales force. Purdue stopped promoting opioids to physicians in February, but ending its sales force engagement removes a touch point for prescribers, Cantor Fitzgerald analyst Brandon Folkes tells investors in a research note titled "Out of Sight, Out of Mind for Purdue." The analyst views Purdue's issues as a positive for Collegium Pharmaceutical's (COLL) Xtampza. He sees Xtampza capturing an increased market share of branded oxycodone scripts from branded OxyContin, which is made by Purdue. Folkes has an Overweight rating on Collegium with a $40 price target.
07/11/18
PIPR
07/11/18
NO CHANGE
Target $34
PIPR
Overweight
Collegium recent share weakness unwarranted, says Piper Jaffray
Piper Jaffray analyst David Amsellem views the recent weakness in shares of Collegium Pharmaceutical as unwarranted. After speaking with management, the analyst has confidence that Xtampza ER prescription growth "will continue to be aggressive" in the second half of 2018 and beyond. Xtampza ER has exclusivity on a number of plans as the only covered extended-release oxycodone product, and there are still significant numbers of patients on certain plans who have yet to be transitioned away from OxyContin, Amsellem tells investors in a research note. He continues to believe that Xtampza ER peak sales of at least $400M-$500M are realistic. The analyst reiterates an Overweight rating on Collegium with a $34 price target.
08/06/18
JANY
08/06/18
NO CHANGE
Target $27
JANY
Buy
Collegium could rally following Q2 earnings, says Janney Montgomery Scott
Janney Montgomery Scott analyst Ken Trbovich attributes recent weakness in Collegium Pharmaceutical shares to three factors: insider sales following the announcement of a CEO transition; recent broader weakness in small-cap stocks; and less confidence in its underlying business trends. Slowing Xtampza growth is not unexpected and prescriptions are high enough to give Trbovich confidence that Collegium should beat his estimates and at least meet, if not beat, consensus. If the company posts a Q2 beat, he thinks the stock could move back above $20 per share, Trbovich said. He keeps a Buy rating and $27 fair value estimate on Collegium shares.
ATRS Antares Pharma
$3.39

0.03 (0.89%)

05/08/18
HCWC
05/08/18
NO CHANGE
Target $4
HCWC
Buy
Antares target raised to $4 on higher Xyosted confidence at H.C. Wainwright
H.C. Wainwright analyst Oren Livnat said that Antares Pharma reported "solid" Q1 results but "most importantly...finally explicitly confirmed a key aspect of the Xyosted filing," specifically that the company already conducted an ambulatory blood pressure monitoring study as part of the supplemental safety study ahead of the NDA submission. That fact, along with Antares' ability to re-submit the NDA just a week after receiving the minutes from the FDA Type-A meeting, increases his confidence in Xyosted approval coming in 2018, Livnat said. He raised his view of Xyosted's probability of success to 70% from 40% and increased his price target to $4 from $3.50 on Antares shares. Livnat keeps a Buy rating on the stock.
10/02/18
JEFF
10/02/18
NO CHANGE
Target $7
JEFF
Buy
Jefferies raises Antares Pharma price target to $7, sees possible upside to $15
Jefferies analyst Anthony Petrone raised his price target on Antares Pharma to $7 from $5, calling FDA approval of Xyosted a "game changer." He does not believe the inclusion of a black box warning in the label is a significant surprise nor a deal breaker for doctors, Petrone tells investors. The analyst, who thinks the company could take anywhere from 20% to 60% of the $1.5B-$2.0B TRT market over time, sees upside to $15 on a strong roll out of Xyosted, he added. Petrone keeps a Buy rating on Antares shares, which are up 17.5% to $3.83 in afternoon trading.
08/17/18
HCWC
08/17/18
NO CHANGE
Target $4.5
HCWC
Buy
H.C. Wainwright ups Antares price target to $4.50 after generic EpiPen approval
After the FDA announced the "long-awaited" approval of Antares Pharma (ATRS) and partner Teva's (TEVA) generic EpiPen, H.C. Wainwright analyst Oren Livnat said his estimates include nearly $40M in peak EpiPen revenue to Antares from the "biggest partnered pipeline opportunity" the company has modeled by his and consensus estimates. Livnat, who said he is not aware of any other substitutable EpiPen generics on the way, views the product as a sustainable contributor and raised his price target on Antares shares to $4.50 from $4.00 following the news. Livnat, who assumes Teva launches quickly after final label packaging, but believes that Teva "unfortunately" will miss the big EpiPen back-to-school prescribing season, keeps a Buy rating on Antares shares.
11/06/18
JEFF
11/06/18
NO CHANGE
Target $8
JEFF
Buy
Antares Pharma price target raised to $8 from $7 at Jefferies
Jefferies analyst Anthony Petrone raised his price target on Antares Pharma shares to $8 from $7 following the company's Q3 report and operating update. Petrone keeps a Buy rating on Antares shares, which are up 3c, or 1%, to $3.53 in afternoon trading.
RCUS Arcus Biosciences
$11.24

-0.37 (-3.19%)

10/09/18
WEDB
10/09/18
INITIATION
Target $22
WEDB
Outperform
Arcus Biosciences initiated with an Outperform at Wedbush
Wedbush analyst Robert Driscoll started Arcus Biosciences with an Outperform rating and $22 price target. The analyst expects the company's focus on extensive biomarker analyses will allow for future clinical strategies with a high likelihood of success. Further, Driscoll believes the breadth and value of its pipeline is undervalued, and sees an attractive entry point ahead of initial efficacy data next year.
04/09/18
SBSH
04/09/18
INITIATION
Target $25
SBSH
Buy
Arcus Biosciences initiated with a Buy at Citi
Citi analyst Robyn Karnauskas started Arcus Biosciences with a Buy rating and $25 price target. The analyst says that while lead compound data is not expected until the first half of 2019, Arcus' proven management and drugs targeting validated pathway make the company competitive despite the crowded landscape in solid tumors.
04/09/18
04/09/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Spirit Airlines (SAVE) initiated with a Neutral at UBS. 2. Northern Oil and Gas (NOG) initiated with a Buy at Stifel. 3. Camtek (CAMT) initiated with an Outperform at Northland. 4. Ares Management (ARES) initiated with a Buy at UBS. 5. Arcus Biosciences (RCUS) initiated with an Outperform at Leerink, a Buy at Citi, and a Neutral at Goldman Sachs. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/09/18
LEER
04/09/18
INITIATION
Target $21
LEER
Outperform
Arcus Biosciences initiated with an Outperform at Leerink
Leerink initiated Arcus Biosciences with an Outperform and $21 price target.
MNLO Menlo Therapeutics
$6.47

0.08 (1.25%)

10/09/18
JEFF
10/09/18
NO CHANGE
Target $7
JEFF
Hold
Menlo Therapeutics price target lowered to $7 from $9 at Jefferies
Jefferies analyst David Steinberg lowered his price target for Menlo Therapeutics to $7 after the company said it will halt serlopitant development in chronic cough with the Phase 2 study failing to meet its endpoints. This marks the second clinical failure this year, but the rest of the program continues on post the prior Phase 2 success in prurigo nodularis and chronic pruritus, Steinberg tells investors in a research note. The analyst keeps a Hold rating on Menlo Therapeutics.
09/06/18
CANT
09/06/18
INITIATION
Target $25
CANT
Overweight
Cantor sees positive data driving Menlo shares higher, starts at Overweight
Cantor Fitzgerald analyst Louise Chen initiated coverage of Menlo Therapeutics with an Overweight rating and $25 price target. The analyst expects pipeline success to drive consensus earnings estimates and the stock higher. Chen believes a "positive, steady stream of pivotal data readouts" for Nularis, Tussix and Psorixa will begin in Q4 of this year.
09/06/18
CANT
09/06/18
INITIATION
Target $25
CANT
Overweight
Menlo Therapeutics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen initiated Menlo Therapeutics with an Overweight and $25 price target.
07/24/18
ROTH
07/24/18
INITIATION
Target $29
ROTH
Buy
Menlo Therapeutics initiated with a Buy at Roth Capital
Roth Capital analyst Yasmeen Rahimi started Menlo Therapeutics with a Buy rating and $29 price target. The analyst cited the company's Phase 3 asset serlopitant for prurigo nodularis, with significant upside potential from Phase 2 programs in psoriasis-related pruritus and refractory chronic cough.

TODAY'S FREE FLY STORIES

SFTBY

SoftBank

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

19:35
09/22/19
09/22
19:35
09/22/19
19:35
Hot Stocks
Fly Intel: Top five weekend stock stories »

Catch up on the…

SFTBY

SoftBank

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

WE

We Company

$0.00

(0.00%)

DB

Deutsche Bank

$7.99

-0.08 (-0.99%)

BNPQY

BNP Paribas

$0.00

(0.00%)

JNJ

Johnson & Johnson

$131.73

1.75 (1.35%)

TEVA

Teva

$7.44

-0.08 (-1.06%)

ENDP

Endo

$3.48

0.115 (3.42%)

MNK

Mallinckrodt

$2.46

0.01 (0.41%)

ABT

Abbott

$83.56

0.35 (0.42%)

AMRX

Amneal Pharmaceuticals

$3.34

0.21 (6.71%)

MYL

Mylan

$21.01

0.03 (0.14%)

MCK

McKesson

$146.83

1.06 (0.73%)

CAH

Cardinal Health

$47.89

-0.14 (-0.29%)

ABC

AmerisourceBergen

$85.13

0.475 (0.56%)

WAB

Wabtec

$74.01

0.26 (0.35%)

CVS

CVS Health

$64.28

0.65 (1.02%)

REAL

RealReal

$17.00

0.21 (1.25%)

CMG

Chipotle

$835.17

3.67 (0.44%)

MCD

McDonald's

$209.44

-1.12 (-0.53%)

YUM

Yum! Brands

$112.31

-1.83 (-1.60%)

WEN

Wendy's

$20.77

0.22 (1.07%)

QSR

Restaurant Brands

$72.64

-1.24 (-1.68%)

CMCSA

Comcast

$46.36

-0.32 (-0.69%)

CMCSK

Comcast

$0.00

(0.00%)

DAL

Delta Air Lines

$58.63

-0.05 (-0.09%)

FANG

Diamondback Energy

$96.90

-0.45 (-0.46%)

EHC

Encompass Health

$64.41

-0.01 (-0.02%)

FB

Facebook

$189.88

-0.27 (-0.14%)

MSFT

Microsoft

$139.34

-1.74 (-1.23%)

PG

Procter & Gamble

$122.22

0.37 (0.30%)

KO

Coca-Cola

$53.90

-0.62 (-1.14%)

PEP

PepsiCo

$134.49

-0.98 (-0.72%)

CL

Colgate-Palmolive

$70.97

0.01 (0.01%)

KMB

Kimberly-Clark

$135.13

0.9 (0.67%)

K

Kellogg

$63.79

0.07 (0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 23

    Sep

  • 24

    Sep

  • 24

    Sep

  • 24

    Sep

  • 24

    Sep

  • 25

    Sep

  • 25

    Sep

  • 26

    Sep

  • 01

    Oct

  • 02

    Oct

  • 02

    Oct

  • 02

    Oct

  • 03

    Oct

  • 08

    Oct

  • 10

    Oct

  • 15

    Oct

  • 16

    Oct

  • 18

    Oct

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 24

    Oct

  • 27

    Oct

  • 29

    Oct

  • 01

    Nov

  • 06

    Nov

  • 12

    Nov

  • 13

    Nov

BGNE

BeiGene

$135.62

2.61 (1.96%)

19:34
09/22/19
09/22
19:34
09/22/19
19:34
Hot Stocks
BeiGene announces results on Tislelizumab from ongoing clinical trials »

BeiGene announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 15

    Oct

  • 27

    Feb

CE

Celanese

$122.73

-1.06 (-0.86%)

19:24
09/22/19
09/22
19:24
09/22/19
19:24
Hot Stocks
Celanese experiences emergency incident at Clear Lake facility »

Celanese experienced an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$379.33

-5.28 (-1.37%)

19:21
09/22/19
09/22
19:21
09/22/19
19:21
Periodicals
Indonesia to fault 737 Max design, oversight lapses in Lion Air crash, WSJ says »

Indonesian investigators…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

AA

Alcoa

$21.70

-0.26 (-1.18%)

19:15
09/22/19
09/22
19:15
09/22/19
19:15
Downgrade
Alcoa rating change at Goldman Sachs »

Alcoa downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

AA

Alcoa

$21.70

-0.26 (-1.18%)

, SCHN

Schnitzer Steel

$23.55

-0.27 (-1.13%)

19:15
09/22/19
09/22
19:15
09/22/19
19:15
Downgrade
Alcoa downgraded to Neutral from Buy at Goldman Sachs »

Goldman Sachs analyst…

AA

Alcoa

$21.70

-0.26 (-1.18%)

SCHN

Schnitzer Steel

$23.55

-0.27 (-1.13%)

CMC

Commercial Metals

$17.94

-0.42 (-2.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

CMC

Commercial Metals

$17.94

-0.42 (-2.29%)

19:08
09/22/19
09/22
19:08
09/22/19
19:08
Downgrade
Commercial Metals rating change at Goldman Sachs »

Commercial Metals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCHN

Schnitzer Steel

$23.55

-0.27 (-1.13%)

19:06
09/22/19
09/22
19:06
09/22/19
19:06
Downgrade
Schnitzer Steel rating change at Goldman Sachs »

Schnitzer Steel…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FNSR

Finisar

$24.31

1.25 (5.42%)

18:15
09/22/19
09/22
18:15
09/22/19
18:15
Hot Stocks
Finisar presents new products, technologies at ECOC 2019 »

Finisar introduced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BNPQY

BNP Paribas

$0.00

(0.00%)

, DB

Deutsche Bank

$7.99

-0.08 (-0.99%)

18:04
09/22/19
09/22
18:04
09/22/19
18:04
Periodicals
Deutsche Bank nearing deal to transfer prime assets to BNP, Reuters says »

Deutsche Bank (DB) is…

BNPQY

BNP Paribas

$0.00

(0.00%)

DB

Deutsche Bank

$7.99

-0.08 (-0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRSK

Verisk Analytics

$158.47

-0.21 (-0.13%)

18:00
09/22/19
09/22
18:00
09/22/19
18:00
Initiation
Verisk Analytics initiated at Keefe Bruyette »

Verisk Analytics assumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$37.92

0.78 (2.10%)

, CMCSA

Comcast

$46.36

-0.32 (-0.69%)

16:58
09/22/19
09/22
16:58
09/22/19
16:58
On The Fly
Box Office Battle: 'Downton Abbey' wins weekend with $31M »

"Box Office Battle" is…

T

AT&T

$37.92

0.78 (2.10%)

CMCSA

Comcast

$46.36

-0.32 (-0.69%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$59.19

-0.19 (-0.32%)

LGF.A

Lionsgate

$9.49

-0.47 (-4.72%)

LGF.B

Lionsgate

$8.88

-0.435 (-4.67%)

DIS

Disney

$132.18

-1.14 (-0.86%)

VIAB

Viacom

$24.92

-0.28 (-1.11%)

VIA

Viacom

$26.67

-0.85 (-3.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Sep

  • 01

    Oct

  • 02

    Oct

  • 03

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 27

    Oct

VIVHY

Vivendi

$0.00

(0.00%)

, MDSO

Medidata

$91.77

-0.04 (-0.04%)

16:01
09/22/19
09/22
16:01
09/22/19
16:01
Periodicals
Vivendi to widen legal battle against Mediaset beyond Italy, Reuters says »

Vivendi (VIVHY) is taking…

VIVHY

Vivendi

$0.00

(0.00%)

MDSO

Medidata

$91.77

-0.04 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFTBY

SoftBank

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

15:57
09/22/19
09/22
15:57
09/22/19
15:57
Periodicals
Some WeWork board members seeing to remove Neumann as CEO, WSJ says »

A bloc of WeWork…

SFTBY

SoftBank

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

WE

We Company

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFTBY

SoftBank

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

15:54
09/22/19
09/22
15:54
09/22/19
15:54
Periodicals
SoftBank turns against WeWork's parent CEO, Reuters reports »

SoftBank (SFTBY), the…

SFTBY

SoftBank

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

WE

We Company

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIAB

Viacom

$24.92

-0.28 (-1.11%)

, VIA

Viacom

$26.67

-0.85 (-3.09%)

15:48
09/22/19
09/22
15:48
09/22/19
15:48
Hot Stocks
Viacom acquires exclusive cable rights to Seinfeld from Sony Pictures Television »

Viacom (VIAB, VIA)…

VIAB

Viacom

$24.92

-0.28 (-1.11%)

VIA

Viacom

$26.67

-0.85 (-3.09%)

SNE

Sony

$59.19

-0.19 (-0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Sep

  • 01

    Oct

  • 02

    Oct

  • 03

    Oct

PWR

Quanta Services

$37.61

-0.28 (-0.74%)

12:22
09/22/19
09/22
12:22
09/22/19
12:22
Conference/Events
Quanta Services management to meet with Stephens »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 13

    Nov

PTEN

Patterson-UTI

$9.66

0.01 (0.10%)

12:21
09/22/19
09/22
12:21
09/22/19
12:21
Conference/Events
Patterson-UTI management to meet with Stephens »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

ESE

Esco Technologies

$78.44

-1.54 (-1.93%)

12:19
09/22/19
09/22
12:19
09/22/19
12:19
Conference/Events
Esco Technologies management to meet with Stephens »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

CSGP

CoStar Group

$595.10

-3.87 (-0.65%)

12:16
09/22/19
09/22
12:16
09/22/19
12:16
Conference/Events
CoStar Group participates in a conference call with Stephens »

Conference call with CFO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 26

    Sep

  • 27

    Sep

  • 13

    Nov

CNNE

Cannae Holdings

$28.05

0.875 (3.22%)

12:02
09/22/19
09/22
12:02
09/22/19
12:02
Conference/Events
Cannae Holdings management to meet with Stephens »

Group Luncheon Meeting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 13

    Nov

ANDE

Andersons

$26.28

-0.56 (-2.09%)

12:01
09/22/19
09/22
12:01
09/22/19
12:01
Conference/Events
Andersons management to meet with Stephens »

Group Luncheon Meeting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 13

    Nov

XGN

Exagen

$18.16

-0.425 (-2.29%)

, DDOG

Datadog

$36.20

-1.26 (-3.36%)

08:40
09/22/19
09/22
08:40
09/22/19
08:40
On The Fly
Opening Day: Datadog rises over 50% in market debut »

Shares of Datadog surged…

XGN

Exagen

$18.16

-0.425 (-2.29%)

DDOG

Datadog

$36.20

-1.26 (-3.36%)

PING

Ping Identity

$19.25

-0.8 (-3.99%)

IGMS

IGM Biosciences

$21.00

-0.7 (-3.23%)

NVST

Envista

$28.80

0.75 (2.67%)

PTON

Peloton

$0.00

(0.00%)

EDR

Endeavor

$0.00

(0.00%)

OPRT

Oportun Financial

$0.00

(0.00%)

WE

We Company

$0.00

(0.00%)

CSCO

Cisco

$49.59

0.38 (0.77%)

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Oct

  • 13

    Nov

  • 26

    Sep

  • 26

    Sep

  • 27

    Sep

PG

Procter & Gamble

$122.22

0.37 (0.30%)

, KO

Coca-Cola

$53.90

-0.62 (-1.14%)

08:17
09/21/19
09/21
08:17
09/21/19
08:17
Periodicals
Kellogg, Coca-Cola among staples stocks for dividends, Barron's says »

Consumer-staples stocks…

PG

Procter & Gamble

$122.22

0.37 (0.30%)

KO

Coca-Cola

$53.90

-0.62 (-1.14%)

PEP

PepsiCo

$134.49

-0.98 (-0.72%)

CL

Colgate-Palmolive

$70.97

0.01 (0.01%)

KMB

Kimberly-Clark

$135.13

0.9 (0.67%)

K

Kellogg

$63.79

0.07 (0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 01

    Oct

  • 03

    Oct

  • 08

    Oct

  • 18

    Oct

  • 22

    Oct

  • 29

    Oct

  • 01

    Nov

CMCSA

Comcast

$46.36

-0.32 (-0.69%)

, CMCSK

Comcast

$0.00

(0.00%)

08:09
09/21/19
09/21
08:09
09/21/19
08:09
Periodicals
Facebook, Microsoft among growth stocks for risky times, Barron's says »

Comcast (CMCSA), Delta…

CMCSA

Comcast

$46.36

-0.32 (-0.69%)

CMCSK

Comcast

$0.00

(0.00%)

DAL

Delta Air Lines

$58.63

-0.05 (-0.09%)

FANG

Diamondback Energy

$96.90

-0.45 (-0.46%)

EHC

Encompass Health

$64.41

-0.01 (-0.02%)

FB

Facebook

$189.88

-0.27 (-0.14%)

JNJ

Johnson & Johnson

$131.73

1.75 (1.35%)

MSFT

Microsoft

$139.34

-1.74 (-1.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 24

    Sep

  • 01

    Oct

  • 02

    Oct

  • 15

    Oct

  • 24

    Oct

  • 27

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.